CommunityDispatch.com
Community News and Information

Contact Us | Submit News |About Us| Subscribe | Home Page
Custom Search


search
For More Current News, Click Here

Search








Clinical Trial Studies
RSS Feed RSS Feed
Last Updated: Jul 11, 2008 - 11:26:39 AM

                                                                                                                              

Impact of Gastric Bypass Surgery on Risk of CVD, Recruiting Patients for Study


By Clinical Trials


Oct 27, 2007 - 7:29:44 AM


 

 

 

 

Impact of Gastric Bypass Surgery on Risk of cardiovascular diseases (CVD) in Type 2 Diabetes Mellitus

This study is currently recruiting participants.
Verified by Vanderbilt University March 2007

Sponsored by: Vanderbilt University
Information provided by: Vanderbilt University
ClinicalTrials.gov Identifier: NCT00444392

Purpose

Central hypothesis is: Gastric bypass surgery reduces the risk of CVD in morbidly obese subjects (defined as BMI ≥35 kg/m2) with T2DM.

To determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with T2DM. I hypothesize that patients with T2DM who undergo gastric bypass surgery will significantly reduce mean levels of risk factors for CVD compared with diabetic individuals with the same BMI who maintain their weight.

Condition Intervention Phase
Obese Patients
Type 2 Diabetes Mellitus
 Behavioral: Calorie controlled diabetic diet for the control patients
Phase III

MedlinePlus  related topics:   Diabetes ;   Obesity

Study Type: Interventional
Study Design: Treatment, Non-Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study

Official Title: Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus

Primary Outcome Measures: 
  • Carotid artery intima-media thickness
  • Brachial artery flow mediated dilation

Secondary Outcome Measures: 
  • Insulin Sensitivity
  • Body Composition
  • Lipoprotein Profiles
  • Inflammatory Markers
Further study details as provided by Vanderbilt University:


Total Enrollment:  60

Study start: March 2007;  Expected completion: August 2010

Patients with type 2 diabetes mellitus (T2DM) are more likely to die from cardiovascular diseases (CVD) than people without diabetes. Furthermore, patients with diabetes have not benefited from the advances in the management of CVD and/or its risk factors that have resulted in a decrease in mortality for CVD patients without diabetes. Short-term studies have demonstrated that weight loss in overweight or obese subjects with T2DM is associated with decreased insulin resistance, substantial improvements in glycemic and lipoprotein profile, and reduction in blood pressure. However, long-term data substantiating that these improvements can be maintained are limited. Obesity, and susceptibility to weight gain, is a chronic condition. Continuous care is required to avoid weight regain especially after intensive weight loss. Morbidly obese patients with body mass index (BMI) over 35 kg/m2 have significant difficulty maintaining weight loss adequate to resolve obesity-related medical conditions by changes in lifestyle or pharmacologic strategies. Currently, surgical treatment of morbid obesity, termed bariatric surgery, appears to be the only modality that results in significant and sustained weight loss along with reversal of diabetes and improvements in cholesterol biosynthesis, and lipoprotein metabolism in morbidly obese patients. Given these observations, we question if patients with T2DM who undergo gastric bypass surgery will significantly reduce levels of abnormalities in vascular structure and function that are central to the development of atherosclerosis. In Specific Aim 1, we will determine whether surgically induced weight loss decreases the risk of CVD in morbidly obese subjects with T2DM. In Specific Aim 2, we will elucidate the mechanisms by which surgically induced weight loss reduces over time the risk of CVD in morbidly obese subjects with T2DM. The proposed study is a prospective cohort clinical trial aimed to evaluate changes over time in cardiovascular structure and function of morbidly obese subjects with T2DM undergoing gastric bypass surgery compared to a matched control group who do not undergo gastric bypass surgery. The results of the proposed studies will provide the foundation for a new clinical strategy aimed to prevent the development of CVD in obese patients with T2DM. Furthermore, they will serve as the baseline for future large scale longitudinal studies based on aggregate occurrence of severe cardiovascular events.

Eligibility

Ages Eligible for Study:  18 Years   -   60 Years,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  1. Clinical diagnosis of T2DM diabetes mellitus with HbA1c ≤ 10.0%

    Any one of the following will be considered to be sufficient evidence that diabetes is present:

    • Current regular use of insulin
    • Current regular use of oral hypoglycemic medication.
    • Documented diabetes by current ADA criteria (98).
  2. Body mass index ≥ 35 kg/m2 in accord with the 1991 NIH obesity surgery consensus conference criteria and stable weight for the previous 3 months (99).
  3. Age between 18-60 years old. Individuals older than 60 years of age are excluded due to their increased risk of mortality and peri-operative morbidity.
  4. Ability and willingness to provide informed consent.
  5. No expectation that subject will be moving out of the area of the clinical center during the next 24 months.

Exclusion Criteria:

  1. Presence of CVD defined as: CAD, electrocardiographic criteria for past myocardial infarction(s), ischemic stroke, peripheral artery bypass surgery, percutaneous transluminal angioplasty, or amputation because of atherosclerotic disease.
  2. Significant non-diabetic co-morbidity affecting life expectancy (e.g., malignancy).
  3. Significant other co-morbidities (e.g. psychiatric disorder) that results in ineligibility for gastric bypass surgery.
  4. Pregnancy or planning pregnancy.
  5. Severe dyslipidemia (triglycerides >600 mg/dl or cholesterol >350 mg/dl).
  6. Uncontrolled hypertension.
  7. Smoking.

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00444392

 

Sherry S. Kernodle, M.Ed., R.D.      615-343-8096    sherry.s.kernodle@vanderbilt.edu
Joan Kaiser, R.N.      615-343-5821    joan.kaiser@vanderbilt.edu

United States, Tennessee
      Vanderbilt University Medical Center, Nashville,  Tennessee,  37232,  United States; Recruiting
Sherry S. Kernodle, M.Ed., R.D.  615-343-8096    sherry.s.kernodle@vanderbilt.edu  
Joan Kaiser, R.N.  615-343-5821   
joan.kaiser@vanderbilt.edu  
Alfonso Torquati, M.D.,  Principal Investigator


Study chairs or principal investigators

Alfonso Torquati, M.D.,  Principal Investigator,  Vanderbilt University   

More Information

Study ID Numbers:  061003; 1K23DK075907-01
Last Updated:  March 6, 2007
Record first received:  March 5, 2007
ClinicalTrials.gov Identifier: 
NCT00444392
Health Authority: United States: Institutional Review Board

Health Check Tools

  • Videos

  • Videos

  •  



    Clinical Trial Studies
    Latest Headlines


    Prostate Cancer Trial: Pomegranate Juice in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery
    Fostering Mothers' Emotionally Responsive Parenting, Recruiting Participants
    Metabolic Study of Sleep Apnea in Men and Women, Recruiting Participants
    Prostate-Specific Antigen Screening in African American Men, Recruiting Participants
    Eating Disorders: Group Parent Training, Recruiting Participants
    Cocaine Addiction Treatment: Clinical Trial Recruiting Participants
    Prostate Biomarker Study Recruiting Participants
    Treatment for Adolescent Marijuana Abuse Clinical Trial

    gastric bypass, gastric bypass surgery, gastric bypass diet, gastric, weight loss surgery